- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark to stop selling tobacco in all store locations
- Study: Higher levels of sleep aid melatonin may reduce prostate cancer risk
- EXPERT BLOG: Provider status for pharmacists — one way or another
TARRYTOWN, N.Y. — While failing to improve overall survival, an investigational treatment for non-small cell lung cancer made by Sanofi-Aventis and Regeneron Pharmaceuticals did keep the disease from worsening and, overall, caused patients to respond to treatment, according to results of a late-stage clinical trial.
Sanofi and Regeneron announced Thursday results of the phase-3 “VITAL” trial of aflibercept. Patients were administered either the drug or placebo in addition to docetaxel chemotherapy.
“Bringing new and innovative cancer therapies to patients can be incredibly challenging, especially in difficult-to-treat cancers, such as second-line non-small cell lung cancer,” Sanofi-Aventis SVP and global oncology head Debasish Roychowdhury said. “Our phase-3 trials of aflibercept in metastatic colorectal cancer and hormone-refractory metastatic prostate cancer are under way to determine the clinical potential of aflibercept for patients with these advanced cancers.”